Resurrect Bio, a London-based agricultural BioTech startup creating disease-resistant crops, has closed its oversubscribed Sequence A funding spherical at €8.8 million ($10.3 million). In February 2026, the corporate made an preliminary shut of over €6.8 million ($8 million) in its Sequence A spherical.
The spherical was led by Corteva by way of its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. The ultimate closing brings Resurrect Bio’s whole funding to about $12.4 million since its inception, together with the 2023 Seed spherical.
Dr Cian Duggan, CEO of Resurrect Bio. “The power of this increase displays rising conviction in what we’re constructing: a scalable, AI-driven platform for resurrecting illness resistance on the planet’s most necessary crops. It’s additionally a validation of what’s attainable whenever you mix the UK’s world-class plant science base with business ambition to translate it into real-world impression.
“We’re increasing our staff, deepening our platforms, and actively in search of joint improvement agreements with seed corporations and breeders who need to convey sturdy resistance traits to farmers.”
Spun out of The Sainsbury Laboratory in Norwich, Resurrect Bio was based in 2022 by Prof. Sophien Kamoun, Prof. Tolga Bozkurt and Dr Cian Duggan. The corporate is on a mission to grow to be the world’s main plant illness resistance firm, creating each in-house traits and collaborating with main seed corporations to guard crops.
Resurrect Bio offers the seed business with a sustainable different to chemical crop safety by resurrecting complicated resistance mechanisms.
The corporate’s core expertise is predicated on the concept pathogens evolve to weaken the crop’s immune response, inflicting illness. The corporate’s strategy is to resurrect the immune system, locking the pathogen out of the crop.
The funds will probably be deployed to scale Resurrect Bio’s three core capabilities: its FloraFold® AI in silico discovery platform, which predicts interactions between plant and pathogen proteins; its high-throughput practical biology platform, which validates these predictions at scale; and its Resurrection platform, which reactivates cryptic resistance mechanisms already current in elite germplasm.
Collectively, these platforms “dramatically” compress the timeline from discovery to deployment in crop.
Elizabeth Klein-Edmonds, Funding Director at Calculus Capital, stated, “Crop illness stays a serious and infrequently missed problem in international agriculture. Resurrect Bio’s revolutionary gene-editing platform, which restores native disease-resistance genes in crops, presents a promising resolution by decreasing dependence on chemical compounds and boosting yields.”
Resurrect Bio claims to be prepared to interact seed corporations and breeders by way of further joint improvement agreements. By these partnerships, it goals to convey sturdy disease-resistance traits to business pipelines sooner than typical breeding can obtain. In March 2026, the corporate introduced its partnership with Corteva Agriscience to develop illness resistance in corn.
